How to Get Rezdiffra (Resmetirom) in Pennsylvania

What Is Rezdiffra and Why Does It Matter for Pennsylvania Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral medication for noncirrhotic MASH with moderate-to-advanced hepatic fibrosis, designated as stages F2 and F3. The FDA granted accelerated approval in March 2024 based on surrogate endpoints from the MAESTRO-NASH trial, which enrolled 966 patients across two dose arms and placebo.

Pennsylvania carries a significant MASH burden. The state's adult obesity rate exceeds 34%, and the Pennsylvania Department of Health has identified liver disease as a growing concern tied to metabolic syndrome. Before resmetirom, no pharmacotherapy directly targeted the fibrotic progression of MASH. Patients relied on weight loss, vitamin E, or off-label pioglitazone, none of which held an FDA indication for this disease.

Resmetirom works as a thyroid hormone receptor beta (THR-beta) agonist. It selectively activates liver THR-beta to reduce hepatic fat, lower atherogenic lipoproteins, and improve fibrosis markers without the cardiac or bone effects associated with systemic thyroid hormone excess. In the MAESTRO-NASH trial, 25.9% of patients on the 80 mg dose achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% on placebo [1]. The FDA label specifies two dose tiers: 80 mg for patients weighing <100 kg and 100 mg for those at or above 100 kg, both taken once daily with food.

Prescriber Eligibility in Pennsylvania

Any physician (MD or DO) licensed in Pennsylvania can prescribe Rezdiffra. Nurse practitioners and physician assistants with independent or collaborative prescriptive authority under Pennsylvania's Medical Practice Act may also write the prescription, provided they hold an active DEA registration and state license.

Most resmetirom prescriptions originate from hepatologists or gastroenterologists, but endocrinologists and primary care physicians familiar with MASH staging can prescribe the drug. The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends that prescribers confirm fibrosis stage before initiating therapy, which typically requires either a FibroScan (vibration-controlled transient elastography) or a liver biopsy. Pennsylvania has over 40 FibroScan-equipped facilities across the state, concentrated in Philadelphia, Pittsburgh, Allentown, and Harrisburg metro areas.

A gastroenterologist quoted in Madrigal's prescriber education materials noted: "The biggest barrier is not the prescription itself but confirming the right fibrosis stage. Patients often present with elevated ALT and steatosis on imaging, but you need quantified fibrosis to meet the label and the payer criteria."

How Telehealth Prescribing Works in Pennsylvania

Pennsylvania permits telehealth prescribing for resmetirom. Good news for patients in rural counties.

The Pennsylvania Telemedicine Act (Act 76, signed 2024) codified audio-video telehealth visits as equivalent to in-person encounters for prescribing purposes. A provider licensed in Pennsylvania can evaluate a patient remotely, review uploaded labs and imaging, and transmit an electronic prescription to a specialty pharmacy. There is no requirement for an initial in-person visit before a telehealth-based resmetirom prescription, though most payers expect documented fibrosis staging from a prior FibroScan or biopsy.

HealthRX and similar telehealth platforms operating in Pennsylvania connect patients with hepatology-trained clinicians who can evaluate MASH severity, order or review FibroScan results, and submit prior authorization paperwork electronically. The typical telehealth workflow proceeds through four steps: (1) patient intake and symptom questionnaire, (2) lab and imaging review, (3) synchronous video consultation, and (4) e-prescribing to a specialty pharmacy.

Patients in counties like Tioga, Potter, and Cameron, where hepatology offices are scarce, benefit most from this model. The nearest FibroScan device may still require a drive, but the prescribing visit itself can happen from home.

Required Labs and Imaging Before Starting Rezdiffra

The pre-prescribing workup is specific and nonnegotiable for both clinical safety and insurance approval.

Baseline labs must include a comprehensive metabolic panel (CMP), complete blood count (CBC), thyroid-stimulating hormone (TSH), and a hepatic function panel with ALT, AST, alkaline phosphatase, and total bilirubin. The FDA prescribing information warns against initiating resmetirom in patients with decompensated cirrhosis (Child-Pugh B or C) and requires TSH monitoring because the drug can suppress TSH levels through its THR-beta mechanism, even though clinical hyperthyroidism is rare at approved doses.

Fibrosis staging is mandatory. The two accepted methods are:

Liver biopsy remains the gold standard. A biopsy graded using the NASH Clinical Research Network (CRN) scoring system confirming fibrosis stage F2 or F3 satisfies both the FDA label and most payer prior authorization forms.

FibroScan (VCTE) offers a noninvasive alternative. A liver stiffness measurement (LSM) between 8.0 and 13.9 kPa generally corresponds to F2-F3 fibrosis, per Baveno VII consensus thresholds. Many Pennsylvania insurers accept FibroScan values in lieu of biopsy for prior authorization, though some commercial plans still require biopsy confirmation for borderline readings.

Additional labs that prescribers commonly order include fasting lipid panel (resmetirom lowers LDL-C by approximately 14% to 22% per the MAESTRO-NASH data), hemoglobin A1c (given the high overlap between MASH and type 2 diabetes), and sex hormone-binding globulin (SHBG), which can rise with THR-beta activation [1].

Prior Authorization for Pennsylvania Insurance Plans

Expect a prior authorization requirement. Nearly all payers mandate it for resmetirom.

Pennsylvania Medicaid covers Rezdiffra with prior authorization through its fee-for-service program and managed care organizations (MCOs) including UPMC Health Plan, Highmark Wholecare, and Aetna Better Health of Pennsylvania. The PA form typically requires:

1. Documented diagnosis of MASH (ICD-10 code K75.81)
2. Fibrosis stage F2 or F3 confirmed by biopsy or validated noninvasive test
3. Evidence that the patient does not have decompensated cirrhosis
4. Prescriber attestation that the patient weighs above or below the 100 kg threshold (determining 80 mg vs. 100 mg dose)
5. Baseline TSH within normal limits

Commercial insurers in Pennsylvania, including Independence Blue Cross, UPMC Health Plan commercial, Highmark, and Geisinger Health Plan, follow similar criteria. Turnaround time for standard PA review is 15 calendar days under Pennsylvania insurance regulations. Urgent PAs must be processed within 24 hours, though MASH rarely qualifies as urgent unless the patient faces rapid fibrosis progression documented by serial imaging.

The Endocrine Society's 2024 clinical guidance on thyroid hormone analogs for liver disease supports resmetirom's use in the F2-F3 population and can serve as a supporting citation when appealing a PA denial. Denial rates for first submissions hover around 15% to 25% nationally, often due to incomplete fibrosis documentation rather than medical disagreement.

Pharmacy Access: Specialty and 503A Compounding Options

Rezdiffra is classified as a specialty medication. Most standard retail pharmacies do not stock it.

In Pennsylvania, resmetirom is dispensed primarily through specialty pharmacy networks. Madrigal Pharmaceuticals partnered with national specialty distributors including Accredo (Express Scripts), AllianceRx Walgreens Prime, and CVS Specialty. These pharmacies ship directly to Pennsylvania addresses and handle benefits verification alongside prior authorization coordination.

Pennsylvania also permits 503A compounding pharmacies to prepare resmetirom formulations under federal and state compounding regulations. A 503A pharmacy operates under a patient-specific prescription and must comply with the Pennsylvania State Board of Pharmacy compounding standards, which align with USP Chapter 795 for nonsterile preparations. Compounded resmetirom may cost less for patients paying out of pocket, particularly those whose insurance denies the branded product.

The list price for branded Rezdiffra is approximately $47,400 per year. Madrigal offers the Rezdiffra Support Program, which includes copay assistance for commercially insured patients (reducing copays to as low as $0 for eligible patients) and a patient assistance program (PAP) for uninsured or underinsured individuals. Pennsylvania patients enrolled in Medicaid MCOs should check whether their specific plan's formulary lists Rezdiffra under specialty tier or requires step therapy.

What the MAESTRO-NASH Trial Showed

The MAESTRO-NASH phase 3 trial published in the New England Journal of Medicine in February 2024 is the key dataset behind the FDA approval. Understanding it helps Pennsylvania patients and their prescribers set realistic expectations.

The trial randomized 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3 to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks. Two co-primary endpoints drove the approval:

MASH resolution without fibrosis worsening occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, versus 9.7% for placebo (P<0.001 for both comparisons) [1].

Fibrosis improvement by at least one stage without NASH worsening was achieved by 24.2% on 80 mg and 25.9% on 100 mg, versus 14.2% on placebo (P<0.001 for the 100 mg arm; P=0.01 for 80 mg) [1].

The trial also documented meaningful reductions in LDL cholesterol (approximately 16%), triglycerides (approximately 20%), and liver fat content measured by MRI-PDFF. Adverse events were generally mild. Diarrhea and nausea occurred more often in the treatment arms (approximately 27% and 15%, respectively) than placebo, but discontinuation rates due to adverse events were similar across groups [1].

Dr. Stephen Harrison, the MAESTRO-NASH principal investigator, stated in the NEJM publication: "These findings establish resmetirom as the first pharmacotherapy to meet both histologic endpoints required for accelerated approval in MASH" [1].

Full confirmatory data from the 54-month MAESTRO-NASH extension are expected in 2028, which will determine whether the accelerated approval converts to full approval based on clinical outcomes such as progression to cirrhosis, liver transplant, or death.

Monitoring While on Rezdiffra in Pennsylvania

Starting the drug is only half the process. Ongoing monitoring is required.

The FDA label recommends checking TSH at baseline, at 4 to 8 weeks after initiation, and every 6 to 12 months thereafter. Because resmetirom suppresses TSH through hepatic THR-beta activation, clinicians must distinguish drug-induced TSH reduction from true thyroid dysfunction. Free T4 and free T3 should be measured if TSH falls below 0.5 mIU/L.

Hepatic function labs (ALT, AST, total bilirubin) are typically repeated at 12 weeks and then every 3 to 6 months. The drug itself lowers ALT in most patients (a median reduction of 30% to 40% was observed in MAESTRO-NASH), so a rising ALT while on therapy warrants investigation for alternative causes, including medication nonadherence or new hepatotoxic exposures [1].

Follow-up FibroScan or repeat biopsy at 12 to 24 months helps assess treatment response. No consensus guideline yet specifies the exact re-staging interval for patients on resmetirom, but the AASLD guidance suggests reassessment at 1 to 2 years for patients on any MASH-directed therapy.

Pennsylvania telehealth providers can order these labs through major national lab networks (Quest Diagnostics and Labcorp both operate draw sites across all 67 Pennsylvania counties), and results upload directly to the patient's electronic health record for remote review.

Cost, Copay Assistance, and Pennsylvania-Specific Coverage Notes

The annual wholesale acquisition cost (WAC) for Rezdiffra sits near $47,400. Out-of-pocket exposure depends entirely on insurance structure.

For commercially insured patients, Madrigal's copay card can reduce monthly costs to $0 for eligible individuals. Patients must have commercial insurance that covers Rezdiffra; the copay card does not apply to government-funded programs like Medicare Part D or Medicaid. The program caps annual assistance at a specified dollar amount, which Madrigal adjusts periodically.

Pennsylvania Medicaid patients face $0 to $3 in copayments per prescription fill under federal Medicaid cost-sharing limits. The prior authorization process, while required, does not typically delay fills beyond 2 to 3 weeks once all documentation is submitted correctly.

Medicare Part D enrollees in Pennsylvania may encounter Tier 5 (specialty tier) placement with 25% to 33% coinsurance after the deductible. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, effective since 2025, limits total exposure for these patients, making resmetirom more financially accessible than the sticker price suggests.

For uninsured patients, Madrigal's patient assistance program provides free drug supply based on income verification (generally below 400% of the federal poverty level). Pennsylvania residents can also contact the Pennsylvania Patient Assistance Program Clearinghouse for additional state-level prescription assistance resources.

Transferring a Rezdiffra Prescription to Pennsylvania

Patients relocating to Pennsylvania or receiving care across state lines can transfer a resmetirom prescription under standard Pennsylvania Board of Pharmacy transfer rules.

A receiving pharmacy in Pennsylvania contacts the originating pharmacy to verify the prescription, remaining refills, and prescriber information. For specialty medications like Rezdiffra, the transfer typically routes to a specialty pharmacy rather than a retail location. The new pharmacy will re-run benefits verification under the patient's current insurance, which may trigger a new prior authorization if the payer has changed. Processing takes 3 to 7 business days in most cases.

Patients using telehealth should confirm that their prescribing clinician holds an active Pennsylvania medical license. A prescription written by a provider licensed only in another state cannot be dispensed by a Pennsylvania pharmacy under telehealth rules. Reciprocity does not apply. The prescriber must independently hold Pennsylvania licensure.